Skip to contentpdufa.bio

TSHA-102 REVEAL

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

TSHA-102 REVEAL is a Taysha Gene Therapies, Inc. program in rett syndrome. Its next catalyst is a Readout in Q2 2027.

TSHA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Rett syndrome. Sponsor: Taysha Gene Therapies, Inc. (TSHA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027TSHA

Specialist biotech funds holding TSHA, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management30,435,190$148.2 millionfiled November 16, 2026
Avoro Capital Advisors23,888,888$116.3 millionfiled November 16, 2026
RTW Investments13,560,258$66.0 millionfiled November 16, 2026
Baker Bros. Advisors4,004,756$19.5 millionfiled November 16, 2026
OrbiMed Advisors2,000,000$9.7 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is TSHA-102 REVEAL's next FDA decision or readout?

The next tracked catalyst for TSHA-102 REVEAL is a Readout in Q2 2027.

What happened at TSHA-102 REVEAL's most recent FDA decision?

No FDA decision for TSHA-102 REVEAL is in our archive yet.

What is TSHA-102 REVEAL used for?

In our records TSHA-102 REVEAL is under review or in development for Rett syndrome.

Who makes TSHA-102 REVEAL?

Taysha Gene Therapies, Inc. (TSHA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.